Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence

  • Technology appraisal guidance
  • TA817
  • Published: 

History

Documents created during the development process.

Expected publication

Final draft guidance: ID2694

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators